FSD Pharma vs Aurora Which Performs Better?

FSD Pharma and Aurora Cannabis are two prominent players in the cannabis industry, both based in Canada. FSD Pharma focuses on the development and production of medical cannabis products, while Aurora Cannabis is a diversified cannabis company with operations across the globe. Both stocks have experienced fluctuations in their value, with FSD Pharma struggling to gain traction in the market while Aurora Cannabis has shown strong growth potential. Investors are closely monitoring these companies as they navigate the evolving regulatory landscape and changing consumer preferences in the cannabis sector.

FSD Pharma or Aurora?

When comparing FSD Pharma and Aurora, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between FSD Pharma and Aurora.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. FSD Pharma has a dividend yield of -%, while Aurora has a dividend yield of 6.17%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. FSD Pharma reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Aurora reports a 5-year dividend growth of -4.77% year and a payout ratio of 102.72%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with FSD Pharma P/E ratio at -0.27 and Aurora's P/E ratio at 14.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. FSD Pharma P/B ratio is 0.30 while Aurora's P/B ratio is 2.00.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, FSD Pharma has seen a 5-year revenue growth of -1.00%, while Aurora's is -0.20%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with FSD Pharma's ROE at -94.58% and Aurora's ROE at 14.00%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.09 for FSD Pharma and NT$66.30 for Aurora. Over the past year, FSD Pharma's prices ranged from $0.09 to $109.19, with a yearly change of 125409.77%. Aurora's prices fluctuated between NT$66.20 and NT$77.00, with a yearly change of 16.31%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.